Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507493 | 0.90 | THRA (0.57) | THRATHRBNPC1RAB9APOLB | |
| SCHEMBL3507489 | 0.90 | THRA (0.57) | THRATHRBNPC1RAB9APOLB | |
| SCHEMBL14416299 | 0.90 | THRA (0.47) | THRATHRBNPC1RAB9APOLB | |
| SCHEMBL3145891 | 0.90 | THRA (0.57) | THRATHRBNPC1RAB9APOLB | |
| SCHEMBL14123994 | 0.86 | NPC1 (0.52) | THRATHRBNPC1RAB9APOLB | |
| SCHEMBL12532976 | 0.84 | RAB9A (0.50) | THRATHRBNPC1RAB9APOLB | |
| Octadecanoic Acid Amide SCHEMBL29097633 | 0.84 | THRA (0.48) | THRATHRBNPC1RAB9ALMNA | |
| SCHEMBL2632344 | 0.84 | BCHE (0.46) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL29097361 | 0.83 | THRA (0.52) | THRATHRBNPC1RAB9APOLB | |
| SCHEMBL31614116 | 0.83 | ALDH1A1 (0.43) | THRATHRBNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-3270977-B1 | OPTICAL PROBES FOR MATRIX METALLOPROTEINASES | UNIV COURT UNIV OF EDINBURGH (GB) | 2020-06-17 | — | — | EP | disclosed |
| US-9649363-B2 | Polyethylene glycol based prodrug of adrenomedullin and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9603936-B2 | Polyethylene glycol based prodrug of adrenomedullin and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| WO-2001029086-A1 | PEPTIDES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | THRA 1017/4885THRB 1286/4885NPC1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.